Human parainfluenza viruses (HPIVs) are medically important respiratory pathogens and are second only to respiratory syncytial virus (RSV) as a major cause of lower respiratory tract (LRT) illness in infants and young children (4, 5, 15, 17, 18, 22) . Although repeat infections in healthy older children and adults are typically less severe, serious LRT illness caused by HPIVs has been reported among immunocompromised individuals (1, 2, 12, 13, (26) (27) (28) and institutionalized elderly individuals (7) .
Of the four recognized serotypes of HPIV (HPIV serotype 1 [HPIV1], HPIV2, HPIV3, and HPIV4) HPIV3 is most commonly associated with serious LRT illness, followed by HPIV1 and HPIV2; HPIV4 is rarely associated with serious illness (9) . The use of classic diagnostic methods like viral isolation and serology can often result in a delay of several weeks before the results are available, and these methods are therefore less useful for making therapeutic decisions (4) . Direct antigen detection methods are widely used for the rapid diagnosis of HPIV infections (11, 20, 21) , but results can be variable (10) , and some HPIV strains may be missed entirely by assays with specific monoclonal antibodies (24) . To address these problems, reverse transcription (RT)-PCR assays that have been shown to provide rapid and sensitive detection of HPIV1 and HPIV3 have been developed (6, 14, 15) . However, all of these methods are monospecific, requiring separate amplifications for each virus. As an alternative, multiplex PCR assays permit simultaneous amplification of several viruses in a single reaction (25) . In this study, we describe novel multiplex RT-PCR assays for the detection and identification of HPIV1, -2, and -3.
MATERIALS AND METHODS
Virus isolates. Cell culture isolates of reference strains of virus obtained from the Centers for Disease Control and Prevention archives were used to develop and standardize the RT-PCR assays. These included (i) HPIV prototype strains C-35 (HPIV1), Greer (HPIV2), and C-243 (HPIV3); (ii) 12 geographically and temporally diverse HPIV isolates from the United States, Canada, and Argentina (HPIV1 from Córdoba, Argentina [1967] Clinical samples. The clinical samples used to evaluate the efficacies of the RT-PCR assays included 45 throat or nasopharyngeal swabs collected from pediatric patients at the Cardinal Glennon Children's Hospital, St. Louis, Mo., and placed in viral transport medium; 10 specimens each were previously culture positive for HPIV1, -2, and -3, and the remaining 15 specimens were positive for other respiratory viruses, including 3 each for RSV, adenovirus, influenza A virus, enterovirus, and rhinovirus. Ten nasopharyngeal specimens from adults culture positive for Streptococcus pneumoniae and culture negative for respiratory viruses were also tested. All clinical samples had been stored at Ϫ70°C.
Primer design and preparation. Previously published sequences of the HPIV hemagglutinin-neuraminidase gene (from 27 HPIV1 isolates, 2 HPIV2 isolates, and 10 HPIV3 isolates) obtained from GenBank were aligned by using the Wisconsin Analysis Package (version 8), Genetics Computer Group, Madison, Wis. External and nested primer sequences were chosen from conserved regions of the hemagglutinin-neuraminidase gene and were designed to achieve optimal performance in a multiplex reaction (Table 1 ). All primers were prepared on a model 394 ABI DNA synthesizer (Perkin-Elmer). Fluorescence-tagged primers were labeled at the 5Ј end with 6-phosphoramidite (FAM; Glen Research). FAM-labeled primers were purified by reversed-phase high-performance liquid chromatography. All other primers were used without further purification.
RNA extraction. RNA was extracted from the clinical samples and virus isolates as described previously (3) . Briefly, 50 l of each sample was treated with 200 l of extraction buffer (4 M guanidinium thiocyanate, 0.5% N-lauryl sarcosine, 1 mM dithiothreitol, 25 mM sodium citrate, and 0.1 mg of glycogen per ml), followed by isopropanol and 70% ethanol precipitations.
RT. The vacuum-dried RNA pellets were resuspended in 10 l of hybridization buffer (300 mM NaCl, 5 mM Tris-HCl [pH 7.5], 1 mM EDTA) containing HPIV1F, HPIV2F, and HPIV3F each at a concentration of 2 M and were denatured for 3 min at 94°C. The RNA template and primers were then allowed to hybridize for 45 min at 50°C. A 40-l volume of RT buffer (10 mM Tris-HCl [pH 8.3]; 6 mM magnesium chloride; 1 mM dithiothreitol; dATP, dGTP, dCTP, and dTTP at a concentration of 1 mM each; and 40 U of RNase inhibitor [RNAsin; Boehringer Mannheim]) containing 50 U of avian myeloblastosis reverse transcriptase (Boehringer Mannheim) was then added, and the mixture was incubated for 1 h at 42°C. The enzyme was finally inactivated by incubation for 5 min at 92°C.
PCR amplification and product detection, two-step method. For primary PCR amplification, 5 l of cDNA prepared in the RT reaction was added to a PCR mixture containing 10 mM Tris-HCl (pH 8.3); 50 mM KCl; 3 mM MgCl; dATP, dCTP, dGTP, and dTTP each at a concentration of 200 M; the primary amplification primers (Table 1) each at a concentration of 2 M; and 1.25 U of Taq polymerase (AmpliTaq; Perkin-Elmer Cetus) in a final volume of 50 l and the mixture was overlaid with mineral oil. Amplification was performed on a model 480 DNA Thermal Cycler (Perkin-Elmer Cetus) programmed for 35 cycles of 1 min of denaturation at 94°C, 1 min of annealing at 50°C, and 1 min of elongation at 72°C; an additional 2 min of denaturation preceded the first cycle, and elongation was extended to 5 min in the last cycle. For nested PCR, 1 l of the primary amplification products was added to 49 l of a new PCR mixture containing nested instead of primary reaction primers (Table 1) , and the thermal cycle program annealing temperature was changed to 58°C. The PCR products were sized by gel electrophoresis on 2% agarose containing 0.5 g of ethidium bromide per ml in TBE (Tris-borate-EDTA) buffer and were visualized under UV light. Standard precautions were taken to avoid carryover contamination. Pipetting was performed with aerosol-resistant tips, and different biosafety cabinets were used for sample extraction and first amplification or nested amplification. Amplicon detection was performed in a different room.
PCR amplification and product detection, one-step method. Primary amplification was performed with the nested primers directly with the RT products, but substituting FAM-labeled forward primers for the unlabeled forward primers. The labeled products were subjected to 6% acrylamide gel electrophoresis under denaturing conditions on an ABI PRISM 377 DNA sequencer (Perkin-Elmer Corp.) and were analyzed with GeneScan Analysis Software (version 2.0.2).
RESULTS
Viral isolates. PCR products of the expected size were obtained with the three HPIV prototype strains when they were tested alone or in a mixed reaction (Fig. 1) . Serial dilution experiments showed that the nested PCR was about 100-fold more sensitive than cell culture isolation for all three types. All reference HPIV isolates were detected and were correctly identified by both the one-step and the two-step procedures. All non-HPIV isolates were PCR negative.
Clinical samples. Of the clinical samples from which HPIVs had previously been isolated, 8 of 10 (80%) samples containing HPIV1, 9 of 10 (90%) samples containing HPIV2, and 9 of 10 (90%) samples containing HPIV3 were RT-PCR positive and were correctly typed by both methods (Fig. 2) . Only three of them were detected after the first amplification in the two-step method. HPIV was reisolated from one of the four clinical samples that were negative by RT-PCR. The isolate was positive for HPIV-1 by RT-PCR, consistent with the original isolate identification. None of the 25 control specimens containing other respiratory viruses or bacterial pathogens were positive. No discrepancies were found between the one-step and two-step procedures.
DISCUSSION
RT-PCR assays for the detection of HPIVs have been described, but they have been limited to the detection of HPIV3 (14, 15) or HPIV1 and HPIV3 (6), without distinguishing between the two serotypes. In contrast, our multiplex assays both detect and differentiate all three medically important HPIV serotypes and provide a sensitive and specific means of identifying HPIVs directly from clinical specimens; 87% (26 of 30) of the clinical samples culture positive for HPIVs were correctly identified, whereas none of the specimens containing a (23) is as described previously.
c Forward primers (ϩ) were 5Ј labeled with FAM fluorescent dye in the one-step multiplex RT-PCR.
diverse group of other respiratory virus and bacterial pathogens were positive.
Although our primers were designed to react with temporally and geographically diverse HPIV isolates, published HPIV sequence data were limited, and therefore unanticipated strain sequence variation in the primer regions could result in occasional false-negative results. This may account for our failure to amplify virus from three of the initially culturepositive clinical samples. However, we believe that the most likely explanation for our false-negative results with these specimens was that the samples were subjected to at least two freeze-thaw cycles between the initial isolation and RT-PCR procedures, possibly causing a decrease in virus titer and RNA degradation. Further testing of diverse fresh clinical samples by RT-PCR will be required to provide a better estimate of the sensitivity and specificity of this assay in a diagnostic setting.
By combining the reactions into fewer assays, the multiplex design is able to achieve substantial savings in time and reagent costs compared with those required for monospecific methods. The two-step multiplex procedure can be readily adapted to laboratories familiar with RT-PCR procedures by conventional DNA detection methods. The one-step procedure offers several important advantages for laboratories with access to the required equipment. PCR products labeled by incorporation of fluorescence-labeled primers can be detected and sized (or typed) with sensitivity comparable to that of nested PCR, but without the added risk of DNA contamination associated with nested PCR procedures; moreover, the GeneScan Analysis Software makes it possible to size bands with single-base-pair accuracy (19) , minimizing the chance of detecting an incorrect but similarly sized product.
In summary, the multiplex RT-PCR assays described here proved to be very effective for the detection and rapid identification of HPIVs. Since primers for other respiratory viruses can be added to the reaction mixture, the efficiencies of these assays can potentially be further improved. However, additional studies will be required to determine the extent to which these assays can complement or replace conventional diagnostic methods.
